SCHEMBL6010969

SCHEMBL6010969

CC1(CN2CCN(C(=O)O)C(Cc3ccc(OC(F)(F)F)cc3)C2)Cn2cc([N+](=O)[O-])nc2O1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 5/20 0.59
PTGS1 P23219 1/20 0.53
SLC6A2 P23975 1/20 0.53
SLC6A4 P31645 1/20 0.53
CHRM1 P11229 1/20 0.47
CACNA1C Q13936 1/20 0.44
SCN5A Q14524 1/20 0.44
ABHD6 Q9BV23 1/20 0.36
DAGLA Q9Y4D2 1/20 0.36
HRH3 Q9Y5N1 2/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
CCR5 P51681 1/20 0.31
AMPD2 Q01433 1/20 0.31
IDH1 O75874 3/20 0.31
GAA P10253 1/20 0.30
CACNA1H O95180 1/20 0.30
ACHE P22303 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6010973 1.00 KCNH2 (0.59) KCNH2PTGS1SLC6A2SLC6A4CHRM1
SCHEMBL6010648 0.90 KCNH2 (0.46) KCNH2PTGS1SLC6A2SLC6A4CHRM1
SCHEMBL6010642 0.90 KCNH2 (0.46) KCNH2PTGS1SLC6A2SLC6A4CHRM1
SCHEMBL6010804 0.89 KCNH2 (0.55) KCNH2PTGS1SLC6A2SLC6A4CHRM1
SCHEMBL6010799 0.89 KCNH2 (0.55) KCNH2PTGS1SLC6A2SLC6A4CHRM1
SCHEMBL6010643 0.89 KCNH2 (0.54) KCNH2PTGS1SLC6A2SLC6A4CHRM1
SCHEMBL6010649 0.89 KCNH2 (0.54) KCNH2PTGS1SLC6A2SLC6A4CHRM1
SCHEMBL6010920 0.88 KCNH2 (0.46) KCNH2PTGS1SLC6A2SLC6A4CHRM1
Hydrochloric Acid SCHEMBL14774897 0.88 KCNH2 (0.47) KCNH2PTGS1SLC6A2SLC6A4CACNA1C
SCHEMBL14775037 0.87 KCNH2 (0.45) KCNH2PTGS1SLC6A2SLC6A4CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KCNH2 3503/4885PTGS1 3838/4885SLC6A2 3396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.